Apr 17th 2013 - Edison Investment Research today published a report on Arrowhead Research Corporation entitled "ARC-520 Set To Become The Key Driver". In summary, the report says:
Arrowhead’s investment case is evolving fast with the recent publication of early but impressive data on its anti-hepatitis B agent, ARC-520, in a chimpanzee model of chronic HBV infection. This showed a 90% reduction in hepatitis B antigens (HBeAg) and HBsAg, sufficient to hold out the potential that the agent could become a functional cure. With the initiation of a Phase I safety study of ARC-520 this year and Phase I/II efficacy study next year, Arrowhead is poised to have a major value inflection point once these data become available.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »